BIONEUTRA GLOBAL : ANNOUNCES CFO APPOINTMENT AND ACQUISITION OF HONG KONG CORPORATION

BioNeutra Global Corporation ('BioNeutra' or the 'Company') (TSXV: BGA), is pleased to announce the appointment of Scott Alanen as Chief Financial Officer ('CFO'), effective today.

Mr. Alanen will lead the Company's global finance strategy and oversee the Company's financial operations. Mr. Alanen is a Chartered Professional Accountant and Chartered Accountant, Chartered Business Valuator and holds an ICD.D designation from the Institute of Corporate Directors. Mr. Alanen has over 15 years of financial and accounting leadership experience in both public and private organizations operating domestically and internationally. Mr. Alanen's diverse background from private equity, real estate based lending, oil and gas and manufacturing will provide valuable insight to the Company. Further Mr. Alanen specifically brings capital raising and debt market expertise that will fuel the Company's growth into new and existing international markets. Together with our Board of Directors, I am delighted to have Mr. Alanen appointed as our CFO,' says Dr. Jianhua Zhu, President and CEO. 'Mr. Alanen will provide BioNeutra with the necessary skills and experience to help us achieve the next level of growth for our shareholders.' Doug Horner, ICD.D and Executive Chairman of the Company says 'Our Board and Executive team are excited to welcome Scott. BioNeutra is poised for an incredible journey and Scott's experience and skill will help us pave the way for success.'

The Company is also pleased to announce that, subject to approval from the TSX Venture Exchange, it has acquired BioNeutra HK Limited ('BioNeutra HK'), a non-arm's length Hong Kong domiciled corporation, as a base to expand the Company's business into Hong Kong and other major metropolitan markets in Asia. The Company has acquired BioNeutra HK from the vendor for cash representing the approximate out-of-pocket expenses incurred by the vendor and the issuance of 200,000 common share purchase warrants at $0.40 for a term of five (5) years. BioNeutra HK had not conducted any material business prior to this transaction. As the acquisition involved a non-arm's length vendor, the Board of Directors of the Company implemented good governance practices with respect to the purchase of BioNeutra HK.

About BioNeutra

BioNeutra is in the business of research and development, production and commercialization of ingredients for nutraceutical, functional and mainstream foods and beverages, with a focus on VitaFiber IMOs. The Company's lead product, VitaFiber, is an advanced functional and health food and beverage ingredient scientifically made from natural agricultural products, is generally regarded as safe (GRAS) by the U.S. Food & Drug Administration, and is European Food Safety Authority and Health Canada approved as a novel food ingredient. VitaFiber is naturally sweet and lower in calories than regular sugar and is a natural source of dietary fiber as it provides low calorie soluble prebiotic fiber for human digestive health. The Company produces VitaFiber using its patented processes that naturally transform starch molecules from agriculture cereal crops including Non-GMO corn, wheat, barley, potato, or tapioca into the functional health molecules of VitaFiber IMO. The VitaFiber manufacturing process is based upon a natural enzymatic conversion of starch molecules without any chemical modification involved, making VitaFiber a natural food and beverage ingredient. VitaFiber is also non-GMO, vegan-friendly, gluten-free, Kosher and Halal certified and available as certified organic. The Company's customers include a mix of small and medium enterprises and a number of high-profile food and beverage manufacturers in Canada, the U.S., Europe, the United Kingdom, and Mexico. VitaFiber is also available for retail purchase across the globe through Amazon.com and other direct-to-consumer retailers.

Contact:

Tel: [phone]

Email: [e-mail]

Forward-Looking Information

This press release may include forward-looking information within the meaning of Canadian securities legislation concerning the business of BioNeutra. Forward-looking information is based on certain key expectations and assumptions made by the management of BioNeutra. Although BioNeutra believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioNeutra can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioNeutra disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any applicable securities laws or any state of the United States and may not be offered or sold in the United States or to the account or benefit of a person in the United States absent an exemption from the registration requirements.

(C) 2019 Electronic News Publishing, source ENP Newswire